EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma

Chiara Brignole, Enzo Calarco, Veronica Bensa, Elena Giusto, Patrizia Perri, Eleonora Ciampi, Maria Valeria Corrias, Simonetta Astigiano, Michele Cilli, Derik Loo, Ezio Bonvini, Fabio Pastorino iD und 1 weitere

Journal for ImmunoTherapy of Cancer · 2023-09 · 11 (9) · e007174

DOI: 10.1136/jitc-2023-007174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 28.09.2023. Verfasst von Chiara Brignole und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Experimental Therapies in Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy. Hauptthemen laut MEDLINE: Immunoconjugates, Neuroblastoma, Antineoplastic Agents. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Associazione Italiana Ricerca Cancro, Associazione Italiana per la Lotta al Neuroblastoma, Italian Ministry of Health, Ricerca Corrente.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

B7-H3 is a potential target for pediatric cancers, including neuroblastoma (NB). Vobramitamab duocarmazine (also referred to as MGC018 and herein referred to as vobra duo) is an investigational duocarmycin-based antibody-drug conjugate (ADC) directed against the B7-H3 antigen. It is composed of an anti-B7-H3 humanized IgG1/kappa monoclonal antibody chemically conjugated through a cleavable valine-citrulline linker to a du ocarmycin-hydroxy b enzamide a zaindole (vc-seco-DUBA). Vobra duo has shown preliminary clinical activity in B7-H3-expressing tumors.

Methods

B7-H3 expression was evaluated by flow-cytometry in a panel of human NB cell lines. Cytotoxicity was evaluated in monolayer and in multicellular tumor spheroid (MCTS) models by the water-soluble tetrazolium salt,MTS, proliferation assay and Cell Titer Glo 3D cell viability assay, respectively. Apoptotic cell death was investigated by annexin V staining. Orthotopic, pseudometastatic, and resected mouse NB models were developed to mimic disease conditions related to primary tumor growth, metastases, and circulating tumor cells with minimal residual disease, respectively.

Results

All human NB cell lines expressed cell surface B7-H3 in a unimodal fashion. Vobra duo was cytotoxic in a dose-dependent and time-dependent manner against all cell lines (IC50 range 5.1–53.9 ng/mL) and NB MCTS (IC50 range 17.8–364 ng/mL). Vobra duo was inactive against a murine NB cell line (NX-S2) that did not express human B7-H3; however, NX-S2 cells were killed in the presence of vobra duo when co-cultured with human B7-H3-expressing cells, demonstrating bystander activity. In orthotopic and pseudometastatic mouse models, weekly intravenous treatments with 1 mg/kg vobra duo for 3 weeks delayed tumor growth compared with animals treated with an irrelevant (anti-CD20) duocarmycin-ADC. Vobra duo treatment for 4 weeks further increased survival in both orthotopic and resected NB models. Vobra duo compared favorably to TOpotecan-TEMozolomide (TOTEM), the standard-of-care therapy for NB relapsed disease, with tumor relapse delayed or arrested by two or three repeated 4-week vobra duo treatments, respectively. Further increased survival was observed in mice treated with vobra duo in combination with TOTEM. Vobra duo treatment was not associated with body weight loss, hematological toxicity, or clinical chemistry abnormalities.

Conclusion

Vobra duo exerts relevant antitumor activity in preclinical B7-H3-expressing NB models and represents a potential candidate for clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesNeuroblastomaAntineoplastic AgentsChildHumansMiceAnimalsDuocarmycinsB7 AntigensAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

drug evaluation, preclinicalimmunotherapyneuroblastoma

Substanzen

ImmunoconjugatesDuocarmycinsAntineoplastic AgentsB7 AntigensAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Laboratory of Experimental Therapies in Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy.
  • Animal Facility, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • MacroGenics Inc, Rockville, Maryland, USA.
  • Laboratory of Experimental Therapies in Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy fabiopastorino@gaslini.org.

ORCID-Profile: Fabio Pastorino, Mirco Ponzoni

Förderung

  • Associazione Italiana Ricerca Cancro
  • Associazione Italiana per la Lotta al Neuroblastoma
  • Italian Ministry of Health, Ricerca Corrente
  • Italian Ministry of Health, Ricerca Finalizzata 5per mille

Zitieren

APA

Brignole, C., Calarco, E., Bensa, V., Giusto, E., Perri, P., Ciampi, E., Corrias, M. V., Astigiano, S., Cilli, M., Loo, D., Bonvini, E., Pastorino, F., & Ponzoni, M. (2023). Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma. Journal for ImmunoTherapy of Cancer, 11(9), e007174. https://doi.org/10.1136/jitc-2023-007174

Vancouver

Brignole C, Calarco E, Bensa V, Giusto E, Perri P, Ciampi E, et al. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma. Journal for ImmunoTherapy of Cancer. 2023;11(9):e007174. doi:10.1136/jitc-2023-007174

BibTeX
@article{Brignole2023,
  author = {Brignole, Chiara and Calarco, Enzo and Bensa, Veronica and Giusto, Elena and Perri, Patrizia and Ciampi, Eleonora and Corrias, Maria Valeria and Astigiano, Simonetta and Cilli, Michele and Loo, Derik and Bonvini, Ezio and Pastorino, Fabio and Ponzoni, Mirco},
  title = {Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {9},
  pages = {e007174},
  doi = {10.1136/jitc-2023-007174}
}
Kostenlos starten →